Abstract
Some patients with hematologic malignancies may benefit from chimeric antigen receptor-T (CAR-T) cell treatment. Usually, the manufacture of this cells is carried out by centralized and specialized cell therapy laboratories that cryopreserve the CAR-T cells in bags and send it for infusion in the patient treatment center. In this context, the thawing and infusion of the CAR-T cell products are critical steps in this custody chain. This article aims to discuss the most relevant points related with the CAR-T cell thawing and infusion and proposes a kind of standard operational protocol (SOP) for these processes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
